计算溶液所需的质量、体积或浓度。
Moexipril HCl是一种口服有效的非巯基血管紧张素转化酶(ACE)抑制剂,IC50为0.041 μM,用于治疗高血压和充血性心脏衰竭。Moexipril HCl is a potent orally active non sulfhydryl angiotensin converting enzyme(ACE) inhibitor
Information
Moexipril HCl (RS-10085) is a potent orally active nonsulfhydrylangiotensin converting enzyme (ACE)inhibitor, used for the treatment of hypertension and congestive heart failure.
In vitro
Moexipril dose-dependently reduces the percentage of damaged neurons, as well as mitochondrial reactive oxygen species generation induced by glutamate, staurosporine or Fe2+/3+. Moexipril and enalapril attenuates staurosporine-induced neuronal apoptosis as determined by nuclear staining with Hoechst 33258.
In vivo
Moexipril (0.3 mg/kg) significantly reduces brain damage after focal ischemia as compared to control mice. Moexipril (0.01 mg/kg) is able to reduce the infarct volume in the rat model after focal cerebral ischemia. Moexipril reduces blood pressure after the first week of treatment but it has no apparent effect on either the proximal tibial metaphysis or the tibial shaft in ovariectomized (OVX) spontaneously hypertensive rats (SHR). Moexipril combined with hydrochlorothiazide (HCTZ) exhibits a much more potent hypotensive effect and has the same effect on bone mass and dynamic end-points as HCTZ alone. Moexiprilat exhibits a higher inhibitory potency than enalaprilat against both plasma ACE and purified ACE from rabbit lung. Moexipril (0.1-30 mg/kg/day) lowers blood pressure and differentially inhibits ACE activity in plasma, lung, aorta, heart and kidney in a dose-dependent fashion. Moexipril (10 mg/kg/day) leads to comparable decreases in blood pressure, inhibition of plasma ACE and reduction of plasma angiotensinogen and to a similar attenuation of the pressor responses to angiotensin I and potentiation of the depressor responses to bradykinin.
Cell Data
cell lines:
Concentrations:
Incubation Time:
Powder Purity:≥99%
H400: 对水生生物毒性极大
P273: 避免释放到环境中。
P501: 将内容物/容器送到批准的废物处理厂处理
P391: 收集溢出物